Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

REM Sleep Behavior Disorder

REM Sleep Behavior Disorder

REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Alterations in Muscle Tone lll

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clozapine induced eosinophilia: An often neglected important adverse effect.

Indian journal of psychiatry·2016

Same author

Trihexyphenidyl dependence-report of two cases.

Indian journal of psychiatry·2011

Same author

Negative symptoms and negative schizophrenia.

Indian journal of psychiatry·2011

Same author

Sexual behaviour in schizophrenic patients on neuroleptic medication.

Indian journal of psychiatry·2011

Same author

Work performance of schizophrenic day boarders in an occupational therapy centre.

Indian journal of psychiatry·2011

Same author

Negative symptoms in schizophrenia and depression.

Indian journal of psychiatry·2011

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

Risperidone induced tardive dyskinesia - a case report.

O V Vasudevan¹, Denzil A Pinto, P S Gopinath

¹O.V. VASUDEVAN, M.B.B.S., Junior Resident, Department of Psychiatry, Fr. Muller's Medical College, Mangalore - 575 002.

Indian Journal of Psychiatry

|January 6, 2011

Summary

This summary is machine-generated.

This case report highlights tardive dyskinesia (TD) in a patient treated with risperidone, a serotonin-dopamine antagonist. Clinicians should remain vigilant for TD development, even with newer antipsychotics.

Keywords:

Tardive dyskinesia atypical antipsychotics risperidone

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Related Experiment Videos

Last Updated: Jun 5, 2026

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Area of Science:

Neuroscience
Psychiatry
Pharmacology

Background:

Risperidone, a second-generation antipsychotic, acts as a serotonin-dopamine antagonist.
While generally considered to have a lower risk of tardive dyskinesia (TD) compared to older antipsychotics, TD has been reported with risperidone.
Tardive dyskinesia is a serious neurological side effect characterized by involuntary movements.

Purpose of the Study:

To report a case of tardive dyskinesia (TD) induced by risperidone.
To increase awareness among clinicians regarding the potential for TD with risperidone treatment.
To discuss risk factors associated with TD development in this specific case.

Main Methods:

Case report presentation.
Review of patient's medical history, including diagnosis, medication, and symptom onset.
Identification of potential risk factors for tardive dyskinesia.

Main Results:

A 56-year-old female with paranoid schizophrenia developed bucco-oro-masticatory involuntary movements after 1 year of risperidone treatment (8 mg/day).
The patient presented with several risk factors for TD, including advanced age, female sex, concurrent use of anticholinergic drugs, and prior neuroleptic-induced parkinsonism.
This case illustrates that even atypical antipsychotics like risperidone can induce TD.

Conclusions:

Clinicians must be aware of the potential for tardive dyskinesia (TD) in patients treated with risperidone.
Risk factors such as age, sex, anticholinergic use, and prior parkinsonism may increase susceptibility to TD with risperidone.
Vigilance and monitoring for TD are crucial in patients receiving risperidone, despite its perceived safety profile.